Imperial College London
Portrait Picture

DrJonathanKrell

Faculty of Medicine, Department of Surgery & Cancer

Clinical SL in Medical Oncology (Gynaecological Oncology)
 
 
 
//

Contact

 

j.krell

 
 
//

Location

 

Institute of Reproductive and Developmental BiologyHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Carter:2018:10.18632/oncotarget.24564,
author = {Carter, P and Alifrangis, CC and Cereser, B and Chandrasinghe, P and Del, Bel Belluz L and Moderau, N and Poyia, F and Schwartzberg, LS and Tabassum, N and Wen, J and Krell, J and Stebbing, J},
doi = {10.18632/oncotarget.24564},
journal = {Oncotarget},
pages = {17589--17596},
title = {Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans},
url = {http://dx.doi.org/10.18632/oncotarget.24564},
volume = {9},
year = {2018}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - We used data obtained by Caris Life Sciences, to evaluate the benefits of tailoring treatments for a breast carcinoma cohort by using tumor molecular profiles to inform decisions. Data for 92 breast cancer patients from the commercial Caris Molecular Intelligence database was retrospectively divided into two groups, so that the first always  followed  treatment  recommendations,  whereas  in  the  second  group  all  patients received at least one drug after profiling that was predicted to lack benefit. The biomarker and drug associations were based on tests including fluorescent in situ hybridization and DNA sequencing, although immunohistochemistry was the main test used.Patients whose drugs matched those recommended according to their tumor profile had an average overall survival of 667 days, compared to 510 days for patients that did not (P=0.0316). In the matched treatment group, 26% of patients were deceased by the last time of monitoring, whereas this was 41% in the unmatched group (P=0.1257). We therefore confirm the ability of tumor molecular profiling to improve survival of breast cancer patients. Immunohistochemistry biomarkers for the androgen, estrogen and progesterone receptors were found to be prognostic for survival.
AU  - Carter,P
AU  - Alifrangis,CC
AU  - Cereser,B
AU  - Chandrasinghe,P
AU  - Del,Bel Belluz L
AU  - Moderau,N
AU  - Poyia,F
AU  - Schwartzberg,LS
AU  - Tabassum,N
AU  - Wen,J
AU  - Krell,J
AU  - Stebbing,J
DO  - 10.18632/oncotarget.24564
EP  - 17596
PY  - 2018///
SN  - 1949-2553
SP  - 17589
TI  - Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans
T2  - Oncotarget
UR  - http://dx.doi.org/10.18632/oncotarget.24564
UR  - http://hdl.handle.net/10044/1/57375
VL  - 9
ER  -
Download